Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.

doi:10.1002/lt.24422

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 1 May 2016

Crittenden Neil E, Buchanan Laura A, Pinkston Christina M, Cave Barbra, Barve Ashutosh, Marsano Luis, McClain Craig James, Jones Christopher M, Marvin Michael R, Davis Eric G, Kuns-Adkins Candice B, Gedaly Roberto, Brock Guy, Shah Malay B, Rosenau Jens, Cave Matthew C

Abstract excerpt

Although combination simeprevir (SIM) plus sofosbuvir (SOF) is an approved regimen for genotype 1 chronic hepatitis C virus (HCV), data regarding its safety and efficacy in liver transplant recipients remain limited. A multicenter retrospective study was performed to determine the efficacy and tolerability of a 12-week regimen of SIM/SOF with or without ribavirin (RBV) in 56 consecutive liver transplant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunosuppression Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Transplant Recipients

Source

Open in PubMed

Identifiers

PMID: 26915588
DOI: 10.1002/lt.24422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.PMID 26915588Read ↗

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Semantic proximity Read ↗

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Semantic proximity Read ↗

Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.Semantic proximity Read ↗

Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.Semantic proximity Read ↗

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.Semantic proximity Read ↗

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.Semantic proximity Read ↗

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.Semantic proximity Read ↗

Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.Semantic proximity Read ↗

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.